公开(公告)号：US20210253534A1

公开(公告)日：2021-08-19

申请号：US17236596

申请日：2021-04-21

Applicant: NOVARTIS AG

Inventor： Donatella CHIANELLI ,  Runyan LI ,  Valentina MOLTENI ,  John NELSON ,  Jason Thomas ROLAND ,  Paul Vincent RUCKER ,  David Charles TULLY ,  Xiaoyang WANG ,  Liladhar Murlidhar WAYKOLE ,  Yubo ZHANG ,  Bo ZHOU

IPC: C07D231/54 ,  C07D471/04 ,  C07D491/052 ,  A61K31/416 ,  A61K31/4162 ,  A61K31/4439 ,  A61K31/4745 ,  C07D471/06

Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).

公开(公告)号：US20180230145A1

公开(公告)日：2018-08-16

申请号：US15889578

申请日：2018-02-06

Applicant: NOVARTIS AG

Inventor： Arnab Kumar CHATTERJEE ,  Advait Suresh NAGLE ,  Prasuna PARASELLI ,  Ravinder Reddy KONDREDDI ,  Seh Yong LEONG ,  Pranab Kumar MISHRA ,  Robert Joseph MOREAU ,  Jason Thomas ROLAND ,  Wei Lin Sandra SIM ,  Oliver SIMON ,  Liying Jocelyn TAN ,  Bryan KS YEUNG ,  Bin ZOU ,  Venkatataiah BOLLU

IPC: C07D471/04 ,  C07D519/00 ,  A61K45/06 ,  A61K31/437 ,  A61K31/506 ,  A61K31/538

CPC classification number: C07D471/04 ,  A61K31/437 ,  A61K31/506 ,  A61K31/538 ,  A61K45/06 ,  C07D519/00 ,  Y02A50/411

Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a Plasmodium parasite, such as malaria.

公开(公告)号：US20170275256A1

公开(公告)日：2017-09-28

申请号：US15598734

申请日：2017-05-18

Applicant: NOVARTIS AG

Inventor： Donatella CHIANELLI ,  Valentina MOLTENI ,  John NELSON ,  Jason Thomas ROLAND ,  Paul Vincent RUCKER ,  David Charles TULLY

IPC: C07D231/54 ,  A61K31/4745 ,  C07D471/06 ,  A61K31/4162 ,  A61K31/416 ,  C07D491/052 ,  C07D471/04 ,  A61K31/4439

CPC classification number: C07D231/54 ,  A61K31/416 ,  A61K31/4162 ,  A61K31/4439 ,  A61K31/4745 ,  C07D471/04 ,  C07D471/06 ,  C07D491/052

Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).

公开(公告)号：US20200247757A1

公开(公告)日：2020-08-06

申请号：US16854762

申请日：2020-04-21

Applicant: NOVARTIS AG

Inventor： Donatella CHIANELLI ,  Runyan LI ,  Valentina MOLTENI ,  John NELSON ,  Jason Thomas ROLAND ,  Paul Vincent RUCKER ,  David Charles TULLY ,  Xiaoyang WANG ,  Liladhar Murlidhar WAYKOLE ,  Yubo ZHANG ,  Bo ZHOU

IPC: C07D231/54 ,  C07D471/04 ,  C07D491/052 ,  A61K31/416 ,  A61K31/4162 ,  A61K31/4439 ,  A61K31/4745 ,  C07D471/06

Abstract: The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).